CD22 and acute lymphoblastic leukemia: Several studies have reported encouraging results from the application of dual CAR-T cells that target both CD19 and CD22 to treat patients with acute lymphoblastic leukemia (ALL), reporting that this therapy is more effective than CD19 CAR-T cell therapy alone (81).